Benefits
Grade I hypertension on antihypertensive therapy (Tomas-Sanchez 2023 PIVOTAL)
Tomas-Sanchez 2023 (PMC10490347, Nutrients 15(17):3691) randomized triple-blind placebo-controlled trial. 81 volunteers with Grade I hypertension already on prescribed antihypertensive drug treatment with persistent uncontrolled BP (average 15-year hypertension history). 250 mg ABG10+® daily vs placebo. Conducted at Hospital Universitari Arnau de Vilanova (Lleida, Spain). NCT04915053. RESULTS: Additional 1.8 mmHg systolic + 1.5 mmHg diastolic BP reduction vs placebo. Mechanism characterization showed: enhanced nitric oxide release, increased antioxidant capacity, decreased ACE (angiotensin-converting enzyme) activity, lower blood uric acid. CLINICALLY MEANINGFUL adjunct evidence.
Hypercholesterolemia cardiovascular risk (Sasaki 2022 crossover)
Sasaki 2022 (PMC8838962, Nutrients 14(3):405) randomized crossover double-blind sustained controlled trial. 67 hypercholesterolemic individuals with LDL ≥115 mg/dL. ABG10+® extract intake combined with dietary recommendations. RESULTS: REDUCTION in DIASTOLIC BLOOD PRESSURE 5.85 mmHg vs placebo (2022 trial result). Cardiovascular risk factor improvements. Crossover methodology provides robust within-subject comparison. Foundational positive cardiovascular trial.
Lipoprotein subclass quality improvements (2025 NMR study)
Recent (2025-2026) randomized triple-blind placebo-controlled trial in 75 Grade I hypertensive participants. 250 mg ABG10+® or placebo daily for 12 weeks. NMR spectroscopy lipoprotein subclass analysis. RESULTS: Significant reduction in total particles and HDL particles. XXL-VLDL particles: significant decrease in free + esterified cholesterol percentage. Large HDL particles: BENEFICIAL REMODELING (increased phospholipid, decreased triglyceride). K-means cluster analysis: participants with adverse baseline metabolic profile experienced greatest triglyceride and VLDL-lipid reductions. QUALITATIVE lipoprotein improvements beyond standard cholesterol panel.
GarDose dose-response trial (NCT06264622) RECRUITING
GARDOSE Trial NCT06264622 — Universitat de Lleida-sponsored quadruple-blind dose response randomized parallel trial. Evaluating low dose vs high dose vs placebo of ABG+/GarlACE Black Garlic Extract on cardiovascular disease risk factors in subjects with Grade I Hypertension. 12-week intervention. Status: RECRUITING. Demonstrates ongoing rigorous clinical development. Dose-finding study will further refine optimal dosing recommendations.
Reduced ACE activity + enhanced NO production (mechanism)
Tomas-Sanchez 2023 mechanistic analysis showed ABG10+® DECREASED ACE activity (angiotensin-converting enzyme) and ENHANCED NITRIC OXIDE production. ACE inhibition is shared mechanism with prescription antihypertensives (lisinopril, captopril, etc.). NO production supports vasodilation. Mechanism distinct from but complementary to existing prescription antihypertensive therapy — explains additional BP reduction in patients already on drugs.
Lower uric acid + antioxidant capacity
ABG10+® reduces blood uric acid levels and increases overall antioxidant capacity. Hyperuricemia is independent cardiovascular risk factor. Mechanism: organosulfur compounds + polyphenols + melanoidins comprehensive antioxidant + xanthine oxidase modulation. Multi-target benefits beyond direct BP/cholesterol effects.
Aging process advantages over fresh/standard aged garlic
Black garlic is whole raw garlic bulb aged at controlled temperatures producing distinct chemical profile: HIGHER SAC accumulation, formation of melanoidins (Maillard reaction antioxidants), 5-hydroxymethylfurfural derivatives, transformation of organosulfur compounds. ABG10+® aging process produces effective clinical doses 60% LOWER than other commercial fresh or aged garlic products per Pharmactive. NO SIGNIFICANT ODOR (vs fresh garlic) due to allicin degradation during aging.
Mechanism of action
ACE inhibition (angiotensin-converting enzyme)
ABG10+® DECREASES ACE activity — same mechanism as prescription ACE inhibitors (lisinopril, captopril, ramipril). Mechanism for blood pressure reduction even in patients on prescription antihypertensive therapy. Demonstrated in Tomas-Sanchez 2023 mechanism analysis.
Nitric oxide production enhancement
Increases endothelial nitric oxide synthase activity — enhanced NO production providing vasodilation and antioxidant effects. Mechanism for BP improvement and broader cardiovascular benefits. Demonstrated mechanistically in Tomas-Sanchez 2023.
S-allyl-L-cysteine (SAC) bioactive accumulation
Aging process accumulates SAC — water-soluble organosulfur compound with cardiovascular, antimicrobial, immunomodulatory, hepatoprotective, antidiabetic, anti-obesity, neuroprotective, renal protective properties (per in vitro and in vivo evidence). Mechanism for multi-system benefits.
Melanoidins (Maillard reaction antioxidants)
Aging produces MELANOIDINS — Maillard reaction products with antioxidant activity. Distinct from typical phenolic antioxidants. Mechanism contributing to overall antioxidant capacity demonstrated in clinical trials.
Antioxidant capacity enhancement
Combined SAC + polyphenols + flavonoids + melanoidins provide comprehensive antioxidant profile. Direct ROS scavenging + endogenous antioxidant enzyme system support. Mechanism for cardiovascular and metabolic benefits.
Xanthine oxidase modulation
ABG10+® reduces blood uric acid levels — mechanism likely involves xanthine oxidase modulation. Hyperuricemia is independent CV risk factor; reduction is added benefit.
Lipoprotein subclass remodeling
2025 NMR study showed ABG10+® induces QUALITATIVE lipoprotein improvements: large HDL particles increase phospholipid + decrease triglyceride content; XXL-VLDL particles reduce cholesterol content. Mechanism beyond traditional 'lower LDL/raise HDL' framework — addresses lipoprotein QUALITY relevant to atherogenic risk.
Clinical trials
Randomized triple-blind placebo-controlled trial (Tomas-Sanchez C, Solà R, Valls RM et al. 2023, Nutrients 15(17):3691, NCT04915053, doi:10.3390/nu15173691). PMC10490347.
81 volunteers with Grade I hypertension already on prescribed antihypertensive drug treatment with persistent uncontrolled BP. Average 15-year hypertension history. Hospital Universitari Arnau de Vilanova (Lleida, Spain) and Atherothrombotic Disease Detection and Treatment Unit. 2-week placebo run-in phase + experimental phase. ABG10+® 250 mg/day vs placebo.
ADDITIONAL 1.8 mmHg SYSTOLIC + 1.5 mmHg DIASTOLIC BP REDUCTION vs placebo in patients ALREADY ON PRESCRIPTION ANTIHYPERTENSIVE THERAPY — clinically meaningful adjunct evidence. MECHANISM: enhanced NO release, increased antioxidant capacity, DECREASED ACE activity, lower blood uric acid. Foundational pivotal trial demonstrating real-world clinical utility as add-on therapy.
Randomized crossover double-blind sustained controlled trial (Sasaki K, Pedret A, Valls RM, Solà R et al. 2022, Nutrients 14(3):405, doi:10.3390/nu14030405). PMC8838962.
67 hypercholesterolemic individuals with LDL-C ≥115 mg/dL. ABG10+® extract daily intake combined with dietary recommendations vs placebo. Crossover design.
Significant reductions in CARDIOVASCULAR DISEASE RISK FACTORS: 5.85 mmHg DIASTOLIC BP REDUCTION vs placebo. Improvements in inflammatory, oxidative, and vasodilatory biomarkers. Foundational positive cardiovascular trial. Crossover methodology strengthens within-subject comparison.
Randomized triple-blind placebo-controlled trial (medRxiv 2026 preprint, doi:10.64898/2026.04.20.26351262v1).
75 Grade I hypertensive participants. 250 mg ABG10+® or placebo daily for 12 weeks. NMR spectroscopy lipoprotein subclass and composition analysis. K-means and PLS-DA metabolic clustering.
Significant reduction in TOTAL PARTICLES and HDL particles. XXL-VLDL particles: SIGNIFICANT DECREASE in free + esterified cholesterol percentage with TRIGLYCERIDE PERCENTAGE INCREASE. Large HDL particles: BENEFICIAL REMODELING (increased phospholipid, decreased triglyceride). Cluster analysis: participants with ADVERSE BASELINE METABOLIC PROFILE experienced GREATEST triglyceride and VLDL-lipid reductions. QUALITATIVE LIPOPROTEIN IMPROVEMENTS beyond standard panel — clinically novel evidence.
About this ingredient
ABG10+® is a STANDARDIZED OPTIMIZED AGED BLACK GARLIC EXTRACT manufactured by PHARMACTIVE BIOTECH PRODUCTS, S.L.U. (Madrid, Spain). Garlic harvested in LAS PEDROÑERAS, Castilla la Mancha, Spain — region traditionally noted for garlic cultivation.
Aging process: WHOLE RAW GARLIC BULBS (Allium sativum L.) aged at controlled temperatures for designated duration via proprietary process. AGING TRANSFORMS WHITE GARLIC INTO BLACK GARLIC: enhances accumulation of bioactive antioxidant compounds including polyphenols, flavonoids, melanoidins (Maillard reaction products), and notably S-ALLYL-L-CYSTEINE (SAC) — water-soluble organosulfur compound. Aging eliminates allicin (compound responsible for typical garlic odor) — ABG10+® has NO SIGNIFICANT GARLIC ODOR.
CLINICAL EFFECTIVENESS at doses 60% LOWER than other commercial fresh or aged garlic products per Pharmactive characterization. CLINICAL EVIDENCE BASE: TOMAS-SANCHEZ 2023 PMC10490347 PIVOTAL Grade I HYPERTENSION RCT (n=81 already on antihypertensives with uncontrolled BP) — ADDITIONAL 1.8 mmHg systolic + 1.5 mmHg diastolic BP reduction with mechanism characterization (enhanced NO, decreased ACE activity, lower uric acid, increased antioxidant capacity). SASAKI 2022 PMC8838962 HYPERCHOLESTEROLEMIA CROSSOVER RCT (n=67) — 5.85 mmHg diastolic BP reduction + improvements in inflammatory/oxidative/vasodilatory biomarkers.
2025 LIPOPROTEIN NMR STUDY (n=75) — qualitative lipoprotein subclass improvements (HDL remodeling with increased phospholipid + decreased triglyceride; XXL-VLDL cholesterol reduction). GARDOSE TRIAL NCT06264622 RECRUITING — dose-response Phase 4 evaluation. Each ABG10+® tablet contains 250 mg ABG extract providing 0.25 mg SAC + standardized processing.
MULTI-TARGET MECHANISMS: ACE INHIBITION (same target as prescription ACE inhibitors), NITRIC OXIDE PRODUCTION ENHANCEMENT, SAC organosulfur bioactivity (cardiovascular + multiple system benefits per in vitro/in vivo), MELANOIDIN antioxidants, XANTHINE OXIDASE modulation (uric acid reduction), LIPOPROTEIN SUBCLASS REMODELING (qualitative HDL/VLDL improvements). EVIDENCE: 3/5 reflects: (1) Tomas-Sanchez 2023 PIVOTAL Grade I hypertension RCT in real-world drug-treated population, (2) Sasaki 2022 PIVOTAL hypercholesterolemia crossover RCT, (3) 2025 NMR lipoprotein subclass evidence (clinically novel), (4) GarDose ongoing dose-response Phase 4, (5) RIGOROUS triple-blind methodology in pivotal trials, (6) MECHANISM CHARACTERIZATION (NO production, ACE inhibition, antioxidant capacity), (7) WELL-CHARACTERIZED standardization (250 mg extract, 0.25 mg SAC), (8) industry-sponsored evidence (Pharmactive) — important context but methodology rigorous, (9) higher evidence level than typical garlic supplements due to clinical optimization. SAFETY: Excellent — food-grade aged garlic origin with extensive clinical safety record.
Best positioned as: (a) GRADE I HYPERTENSION ADJUNCT for those on antihypertensive medication with persistent uncontrolled BP (real-world clinical context per Tomas-Sanchez 2023), (b) HYPERCHOLESTEROLEMIA ADJUNCT (Sasaki 2022 evidence for diastolic BP + lipid effects), (c) METABOLIC SYNDROME adjunct (multi-target benefits), (d) ANTIOXIDANT/ANTI-INFLAMMATORY general support, (e) DAILY long-term use acceptable based on safety profile, (f) NO GARLIC ODOR — practical advantage over fresh garlic supplements, (g) higher-evidence than typical 'aged garlic supplement' due to standardization + multiple RCTs, (h) industry-sponsored evidence — independent replication welcomed but methodology sound. Honest framing: ABG10+® has rigorous evidence — pivotal Tomas-Sanchez 2023 Grade I hypertension RCT in drug-treated population with mechanism characterization is methodologically robust, Sasaki 2022 crossover RCT in hypercholesterolemia provides additional foundational evidence, 2025 NMR lipoprotein subclass evidence is clinically novel. Pharmactive's optimized aging process appears to produce real clinical advantages over standard aged garlic.
Industry sponsorship warrants caveat but transparent. Reasonable cardiovascular adjunct based on evidence — particularly compelling for those on existing antihypertensive therapy with persistent residual BP elevation.